Results 81 to 90 of about 67,047,750 (228)

New Pharmacological Treatment Of Heart Failure With Reduced Ejection Fraction

, 2022
Heart failure has contributed to a rising mortality and hospitalization rate in the past decades despite several breakthrough discoveries and advances in its management. Approximately 50% of all patients with Heart failure have heart failure with reduced
Obi, Precious
core  

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Heart failure with mid-range ejection fraction: Two overlapping entities? Reply

CorSalud, 2019
Heart failure with mid-range ejection fraction: Two overlapping entities ...
Patricia Javaloyes, Víctor Marquina, Pere Llorens   +2 more
doaj  

Geographical Variations in Patients with Heart Failure and Preserved Ejection Fraction: A Sub-Group Analysis of the APOLLON Registry

Balkan Medical Journal, 2019
Background: Clinical characteristics of patients with heart failure may vary geographically. However, limited data are available regarding the geographical differences of patients with heart failure and preserved ejection fraction.
Bülent Özlek, Eda Özlek, Hicaz Zencirkıran Ağuş, Mehmet Tekinalp, Serkan Kahraman, Oğuzhan Çelik, Cem Çil, Özcan Başaran, Volkan Doğan, Bedri Caner Kaya, İbrahim Rencüzoğulları, Altuğ Ösken, Lütfü Bekar, Mustafa Ozan Çakır, Yunus Çelik, Kadir Uğur Mert, Kadriye Memiç Sancar, Samet Sevinç, Gurbet Özge Mert, Murat Biteker   +19 more
doaj   +1 more source

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Heart Failure And Midrange Ejection Fraction: Implications Of Recovered Ejection Fraction For Exercise Tolerance And Outcomes

, 2016
Evidence-based therapies for heart failure (HF) differ significantly according to left ventricular ejection fraction (LVEF). However, few data are available on the phenotype and prognosis of patients with HF with midrange LVEF of 40% to 55%, and the ...
W; West, DE; Shah, Nadruz, E; Santos, JD; Forman, M; Skali, AM, H; Groarke   +7 more
core   +2 more sources

Heart failure with mid-range left ventricular ejection fraction: New entity?

CorSalud, 2018
Currently, a new classification of patients with heart failure (HF) according to the left ventricular ejection fraction (LVEF), the HF with mid-range LVEF (HFmrEF) between 40 and 49% is described.
Patricia Javaloyes, Víctor Marquina, Pere Llorens   +2 more
doaj  

Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction : trading therapy for prevention

, 2017
This article refers to 'Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes,' by C.Matyas et al., published in this issue on pages 326 ...
Paulus, Walter J., L. van Heerebeek, W. J. Paulus, van Heerebeek, Loek, Walter J. Paulus, Loek van Heerebeek, M. Guazzi, Marco Guazzi, Guazzi, Marco   +8 more
core   +1 more source

Prognostic value of left atrial reverse remodelling in heart failure with preserved ejection fraction

, 2023
Objectives Left atrial reverse remodelling (LARR) reflects an improvement in the function or structure. However, it is unclear whether the presence of LARR is associated with better outcomes in patients with heart failure with preserved ejection ...
Zhao, Shuang, Tse, Gary, Bai, Lin, Liu, Ying, Sun, Yuxi, Liu, Jiani, He, Hongyan, Fu, Qiang, Tse, Mimi   +8 more
core   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source